Information Provided By:
Fly News Breaks for February 20, 2020
RETA
Feb 20, 2020 | 06:44 EDT
Citi analyst Yigal Nochomovitz says Reata Pharmaceuticals remains his top pick for 2020 with a Buy rating and $328 price target. The analyst expects approvals for both bardoxolone methyl in Alport syndrome and omaveloxolone in Friedreich's Ataxia. New Drug Application submissions for both are expected in 2020, Nochomovitz tells investors in a research note.
News For RETA From the Last 2 Days
There are no results for your query RETA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.